• City Therapeutics

  Participated · Series B · Jun 2026

  City Therapeutics is developing a pipeline of RNA interference (RNAi) therapeutics using a next‑generation RNAi engineering platform. The company has initiated a Phase 1 clinical trial of CITY‑FXI targeting Factor XI and reported positive preclinical data for CITY‑RBP4, a candidate for Stargardt disease. It has announced strategic collaborations with Bausch + Lomb and Biogen and plans to advance two programs to clinical stage this year while progressing additional programs toward the clinic by year‑end 2026. City Therapeutics is based in Cambridge, MA, and has raised over $230 million from life sciences investors to date. The recent $99.5 million Series B is intended to accelerate its platform, expand the pipeline, and support business development and partnership activities.

• Vitestro

  Participated · Series B · Mar 2026

  Vitestro is a Netherlands-headquartered medical-robotics company focused on automating diagnostic blood draws with its Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™). The CE-marked system combines multimodal imaging, advanced robotics, and artificial intelligence to locate veins, guide needle insertion, and collect blood with high precision and consistency. By standardizing venous access, the platform aims to alleviate staffing shortages, reduce variability, and improve patient experience in high-volume outpatient environments. Vitestro is currently deploying Aletta® in clinical and pre-commercial sites across Europe while pursuing a U.S. FDA De Novo clearance. Proceeds from its latest financing will fund next-generation product development, manufacturing scale-up, additional clinical studies, and the build-out of global commercial infrastructure.

• Cellular Origins

  Participated · Series A · Dec 2025

  Cellular Origins, led by CEO Edwin Stone, provides a factory-led automation platform that adapts to existing cell-therapy manufacturing processes and facilities. Its Constellation ecosystem integrates mobile robotics and automated sterile welding with established bioprocess instruments to streamline and scale production. The technology is already in use by industry leaders such as Cytiva, Fresenius Kabi, Thermo Fisher Scientific and Wilson Wolf, demonstrating early commercial adoption. With fresh capital, the company plans to expand its commercial team and widen the range of unit operations that can be integrated into Constellation. It also intends to build the systems and infrastructure required for full manufacturing and services scale-up. Looking ahead, Cellular Origins aims to extend its capabilities beyond cell therapies into the broader Advanced Therapy Medicinal Products (ATMP) sector, positioning itself for growth in adjacent markets.

• Akadeum Life Sciences

  Participated · Equity · Jun 2025

  Akadeum Life Sciences pioneers flotation-based cell separation technologies that enable more effective, scalable, and gentle cell isolation. The company commercialized industry-first innovations including scalable negative selection, multiplex separation, microbubble-based nucleic acid extraction, and a high-capacity T cell separation chamber. It recently launched a GMP-compliant product suite designed for use in clinical trials and demonstrated the ability to integrate microbubbles into many existing cell therapy manufacturing tools. Akadeum says its platform has shown therapeutic relevance in preclinical animal models for cancer treatment and is driving adoption through data showing more viable cells, higher yields, and easier workflows versus conventional methods. The company announced a $20M+ financing to scale commercial operations and especially to support customers entering clinical trials. Akadeum has gained industry momentum and engagement from partners and customers including Catalent, Charles River Laboratories, ElevateBio, and Lonza. Akadeum Life Sciences develops a floatation-based, microbubble separation platform (Buoyancy Activated Cell Sorting, BACS™) for sample preparation in research, diagnostics, and cell therapy. Its technology floats target cells, nucleic acids and other biological targets to the top of a sample to enable capture, addressing volume and throughput restrictions of existing methods. The company was the first to commercialize BACS microbubble kits for cell isolation applications. Akadeum positions its solutions as exceeding the performance, system cost, and scalability of current technologies. Future plans stated in the article include advancing global commercialization, developing new business-to-business partnerships, and expanding R&D and new product development. The company is located in Ann Arbor, Michigan. Akadeum Life Sciences develops technology that enables fast, easy removal of target cells from biological samples. Its product uses BACS™ (buoyancy-activated cell sorting) with tiny floating "microbubbles" and disposable microbubble collectors to acquire target cells. The microbubbles are introduced into samples, attach to target cells such as T cells, B cells, or cancer cells, and gently float them to the top for easy capture and removal. The company was founded in 2014 and is led by CEO Brandon McNaughton and CTO John Younger; it is based in Ann Arbor, Michigan. Akadeum raised $1M in seed funding and will use the funds to continue product development and increase sales and marketing. The company plans a Series A financing round in 2016.

• Vittoria Biotherapeutics

  Participated · Equity · Nov 2024

  Vittoria Biotherapeutics is a clinical-stage immunotherapy company developing novel cell therapies for hard-to-treat diseases. Its lead program, VIPER-101, is a gene-edited, autologous dual-population T cell therapy designed to target CD5 for patients with T-cell lymphoma. VIPER-101 and other assets leverage the company’s proprietary Senza5 platform, which enhances T cell effector function by abrogating CD5-mediated immunosuppression and employs a rapid five-day manufacturing process. Senza5 has demonstrated outstanding preclinical anti-tumor efficacy across a range of liquid and solid tumor models, and the broader pipeline includes programs targeting solid tumors and autoimmune diseases. The company recently completed a $25 million private financing to support clinical proof-of-concept for VIPER-101. The VIPER-101 Phase 1 trial is actively recruiting patients (ClinicalTrials.gov NCT06420089). The technology is exclusively licensed from the University of Pennsylvania, which also holds equity and has existing financial relationships with Vittoria.

No current team members are available.